Vue.component('cvdm-overview', { template: '
The percentage of individuals ≥18 years of age who have type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) that are prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist or sodium-glucose cotransporter-2 (SGLT-2) inhibitor with proven cardiovascular benefit during the measurement year.
' + 'A higher rate indicates better performance.
' + 'Intended Use
' + 'Performance measurement for health plans.
' + 'Data Sources
' + 'Medical and prescription claims data.
' + 'Denominator
' + 'Individuals with a diagnosis of type 2 diabetes and established ASCVD.
' + 'Exclusions
' + 'Numerator
' + 'Individuals with ≥1 prescription claims for a GLP-1 receptor agonist or SGLT-2 inhibitor with a proven cardiovascular benefit during the measurement year.
' + '